Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK to address surgery cancellations

This article was originally published in Clinica

Executive Summary

"There is no room for complacency." This is how the UK's Department of Health underlined its commitment to tackle surgery cancellations, in light of data released today. In England, during the period July-September (Q2 2006-07), 12,275 operations (0.8% of all elective surgery) were cancelled at the last minute for non-clinical reasons, a small improvement on the 13,058 of Q2 2005-06. Delays in re-arranging the operation, although significantly better than a year ago, remain a source of concern: 637 (5.2%) cases were not treated within 28 days; last year, the figure was 1,160 (8.9%). At the end of October 2006, the number of patients waiting in England over 13 weeks for an operation stood at 188,300, down 2.3% from September and 9.4% since October 2005. The NHS performs 662,000 more operations per year now than in 1997, the DoH notes.

You may also be interested in...



Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel